HOW AND WHERE TO BUY GEMIFLOXACIN MESYLATE (FACTIVE) 320 MG TABLETS OR CAPSULES ONLINE:
FACTIVE (GEMIFLOXACIN MESYLATE) TABLETS: PHARMACOKINETICS IN SPECIAL POPULATIONS
The pharmacokinetics of Gemifloxacin Mesylate (Factive) in pediatric subjects have not been studied.
In adult subjects, the pharmacokinetics of gemifloxacin are not affected by age.
There are no significant differences between Factive (Gemifloxacin) tablets pharmacokinetics in males and females when differences in body weight are taken into account. Population pharmacokinetic studies indicated that following administration of 320 mg gemifloxacin, AUC values were approximately 10% higher in healthy female patients compared to males. Males and females had mean AUC values of 7.98 mcg·hr/mL (range, 3.21 - 42.71 mcg·hr/mL) and 8.80 mcg·hr/mL (range, 3.33 - 47.73 mcg·hr/mL), respectively. No gemifloxacin dosage adjustment based on gender is necessary.
The pharmacokinetics following a single 320 mg dose of gemifloxacin were studied in patients with mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) liver disease. There was a mean increase in AUC (0-inf) of 34% and a mean increase in Cmax of 25% in these patients with hepatic impairment compared to healthy volunteers.
The pharmacokinetics of a single 320 mg dose of gemifloxacin were also studied in patients with severe hepatic impairment (Child-Pugh Class C). There was a mean increase in AUC (0-inf) of 45% and a mean increase in Cmax of 41% in these subjects with hepatic impairment compared to healthy volunteers.
These average pharmacokinetic increases are not considered to be clinically significant. There was no significant change in plasma elimination half-life in the mild, moderate or severe hepatic impairment patients. No dosage adjustment is recommended in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment.
Results from population pharmacokinetic and clinical pharmacology studies with repeated 320 mg doses indicate the clearance of gemifloxacin is reduced and the plasma elimination is prolonged, leading to an average increase in AUC values of approximately 70% in patients with renal insufficiency. In the pharmacokinetic studies, gemifloxacin Cmax was not significantly altered in subjects with renal insufficiency. Dose adjustment in patients with creatinine clearance > 40 mL/min is not required. Modification of the dosage is recommended for patients with creatinine clearance <= 40 mL/min.
Hemodialysis removes approximately 20 to 30% of an oral dose of Gemifloxacin (Factive) tablets from plasma.
Order Factive (Gemifloxacin Mesylate) Online
Factive prescribing information